{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-042846","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2026-06-12T20:10:37+00:00","discovered_at":"2026-06-12T20:12:00.360467+00:00","generated_at":"2026-06-12T20:23:46.962656+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"CAMP4 stockholders approve 2024 Plan amendment; Board adopts 2026 Inducement Plan (500K shares) for new hires","bullets":["Stockholders approved amendment to 2024 Equity Incentive Plan to include pre-funded warrants in evergreen share calculation.","Board adopted 2026 Inducement Plan reserving 500,000 shares of common stock for inducement grants to new employees without stockholder approval.","Annual meeting results: re-elected directors Holtzman, Stewart, Young; ratified Ernst & Young as auditor for FY2026.","Plan amendment and inducement plan both effective as of June 10, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-042846","json":"https://secwatch.observer/filing/0001628280-26-042846.json","markdown":"https://secwatch.observer/filing/0001628280-26-042846.md","text":"https://secwatch.observer/filing/0001628280-26-042846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026042846/0001628280-26-042846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026042846/camp-20260610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T20:23:46.962656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77cbeb9302c5b7e091a2d34990a01b77df4370e0","claim":"Camp4 Therapeutics Corp shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.","evidence_excerpt":"2. The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026, based on the following votes: For Against Abstain 39,998,507 127 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026042846/0001628280-26-042846-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"8be9faca86bc7804610a590b9ae264795da1ff18","claim":"Camp4 Therapeutics Corp shareholders approved Amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan at the 2026-06-10 meeting.","evidence_excerpt":"3. The stockholders approved the amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan, based on the following votes: For Against Abstain Broker Non-Votes 27,002,145 10,023,588 199,455 2,773,446","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026042846/0001628280-26-042846-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"8fcf606da82826ac657c68f72a2b33866fe289f2","claim":"Camp4 Therapeutics Corp shareholders approved Election of Class II directors at the 2026-06-10 meeting.","evidence_excerpt":"1. The following nominees were elected as the Company’s Class II directors, each to serve for a three-year term until the 2029 annual meeting of stockholders, and until his successor shall have been duly elected and qualified, based on the following votes: Nominees For Against Abstain Broker Non-Votes Steven Holtzman 29,233,042 7,992,146 — 2,773,446 Murray Stewart, DM FRCP 31,669,512 5,555,665 11 2,773,446 Richard Young, PhD 29,212,962 8,012,214 12 2,773,446","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026042846/0001628280-26-042846-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}